Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВПО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6
Список исп. литературыСкрыть список 1. Абрамов В.А., Денисов Е.М., Ряполова Т.Л. Атипичный антипсихотик Солиан: результаты исследования STAR. Нейро news. 2008; 2: 78–82. / Abramov V.A., Denisov E.M., Riapolova T.L. Atipichnyi antipsikhotik Solian: rezul'taty issledovaniia STAR. Neiro news. 2008; 2: 78–82. 2. Аведисова А.С., Ястребов Д.В. Амисульприд (Солиан): наиболее атипичный из атипичных нейролептиков. Фарматека. 2006; 2: 2. / Avedisova A.S., Iastrebov D.V. Amisul'prid (Solian): naibolee atipichnyi iz atipichnykh neiroleptikov. Farmateka. 2006; 2: 2. [in Russian] 3. Андреев Б.В., Астахова Л.В., Богданов Н.А. и др. Солиан: опыт использования в России. 2006; 1. / Andreev B.V., Astakhova L.V., Bogdanov N.A. i dr. Solian: opyt ispol'zovaniia v Rossii. 2006; 1. [in Russian] 4. Данилов Д.С. Современные классификации антипсихотических средств и их значение для клинической практики (современное состояние вопроса и его перспективы). Обозрение психиатрии и мед. психологии. 2011; 3: 36–42. / Danilov D.S. Sovremennye klassifikatsii antipsikhoticheskikh sredstv i ikh znachenie dlia klinicheskoi praktiki (sovremennoe sostoianie voprosa i ego perspektivy). Obozrenie psikhiatrii i med. psikhologii. 2011; 3: 36–42. [in Russian] 5. Дробижев М.Ю., Овчинников А.А. Антипсихотики: меняем старые поколения на новую классификацию? Соц. и клин. психиатрия. 2010; 2: 80–6. / Drobizhev M.Iu., Ovchinnikov A.A. Antipsikhotiki: meniaem starye pokoleniia na novuiu klassifikatsiiu? Sots. i klin. psikhiatriia. 2010; 2: 80–6. [in Russian] 6. Медведев В.Э. Лечение шизофрении современными атипичными антипсихотическими препаратами (учебно-методическое пособие). М.: Конти-Принт, 2014. / Medvedev V.E. Lechenie shizofrenii sovremennymi atipichnymi antipsikhoticheskimi preparatami (uchebno-metodicheskoe posobie). M.: Konti-Print, 2014. [in Russian] 7. Медведев В.Э. Возможность и оправданность перевода на атипичные антипсихотики больных шизофренией. Психиатрия и психофармакотерапия. 2013; 5: 23–8. / Medvedev V.E. Vozmozhnost' i opravdannost' perevoda na atipichnye antipsikhotiki bol'nykh shizofreniei. Psikhiatriia i psikhofarmakoterapiia. 2013; 5: 23–8. [in Russian] 8. Медведев В.Э. Диагностика латентного течения и первого эпизода шизофрении. Психиатрия и психофармакотерапия. 2012; 6: 65–9. / Medvedev V.E. Diagnostika latentnogo techeniia i pervogo epizoda shizofrenii. Psychiatry and psichopharmacotherapy. 2012; 6: 65–9. [in Russian] 9. Медведев В.Э. Негативные расстройства: понятие и терапия. Психиатрия и психофармакотерапия. 2011; 6: 16–21. / Medvedev V.E. Negativnye rasstroistva: poniatie i terapiia. Psychiatry and psichopharmacotherapy. 2011; 6: 16–21. [in Russian] 10. Снедков Е.В. Атипичные антипсихотики: поиск решения старых и новых проблем. Психиатрия и психофармакоте-рапия. 2006; 4: 45–50. / Snedkov E.V. Atipichnye antipsikhotiki: poisk resheniia starykh i novykh problem. Psychiatry and psichopharmacotherapy. 2006; 4: 45–50. [in Russian] 11. Тарасевич Л.А. Опыт применения амисульприда у больных шизофренией в условиях принудительного лечения. Обозрение психиатрии и мед. психологии. 2005; 4: 31–4. / Tarasevich L.A. Opyt primeneniia amisul'prida u bol'nykh shizofreniei v usloviiakh prinuditel'nogo lecheniia. Obozrenie psikhiatrii i med. psikhologii. 2005; 4: 31–4. [in Russian] 12. Точилов В.А., Протальская А.Г. Нейролептики – производные замещенных бензамидов в психиатрической практике. Соц. и клин. психиатрия. 1998; 3: 137–45. / Tochilov V.A., Protal'skaia A.G. Neiroleptiki – proizvodnye zameshchennykh benzamidov v psikhiatricheskoi praktike. Sots. i klin. psikhiatriia. 1998; 3: 137–45. [in Russian] 13. Agelink MW, Majewski T, Wurthmann C et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001; 21 (1): 8–13. / [in Russian] 14. Amore M, Jori M. Faster response on amisulpride 50 mg versus sertraline 50–100 mg in patients with dysthymia or double depression: A randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16 (6): 317–24. 15. Barrett RJ, Ginos JZ, Lokhandwala MF. Evaluation of peripheral dopamine receptor and alpha-adrenoceptor blocking activity of sulpiride. Eur J Pharmacol 1982; 4: 273–81. 16. Beasley CMJr, Stauffer VL, Liu-Seifert H et al. All-cause treatment discontinuation in schizophrenia during treatment with olanza-pine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol 2007; 27 (3): 252–8. 17. Bech P, Lunde M, Bech-Andersen G et al. Psychiatric outcome studies (POS): does treatment help the patients? A Popperian approach to research in clinical psychiatry. Nord J Psychiatry 2007; 61 (Suppl. 46): 4–34. 18. Bertolin GJ, Fuente P, Vila Navarro C. Amisulpride in delusional disorders. An observational study. Arch Psiquiatria 2005; 68 (4): 301–8. 19. Bogetto F, Barzega G, Bellino S et al. Drug treatment of dysthymia. A clinical study. Rivista di Psichiatria 1997; 32 (1): 1–5. 20. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: Placebo controlled studies of amisulpride versus imipramine, versus amineptine. Eur Psychiatry 1996; 11 (Suppl. 3): 135–40. 21. Boyer P, Lecrubier Y, Peuch A et al. Treatment negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995; 166: 68–72. 22. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiol 1999; 39 (1): 25–32. 23. Burns T, Bale R. Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 2001; 29 (6): 451–66. 24. Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000; 15: 321–9. 25. Cassano G, Jori M. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression. A randomized, double-blind,parallel group study. Int Clin Psychopharmacol 2002; 17 (1): 27–32. 26. Carta MG, Zairo F, Mellino G et al. An open label follow-up study on amisulpride in the add-on treatment of bipolar I patients. Clin Pract Epidemiol in Mental Health 2006; 2: 19. 27. Ceskova E. Deniban in the treatment of dysthymia. Ceska Slove Psychiatr 2007; 103 (2): 73–9. 28. Chabannes JP, Bazin N, Leguay D et al. Two-year study of relapse prevention by a new education program in schizophrenic patients treated with the same antipsychotic drug. Eur Psychiatry 2008; 23 (1): 8–13. 29. Chiaie R, Caliari P. Chronic mild depressive symptoms: Rational use of amisulpride. Rivista di Psichiatria 1997; 32 (Suppl. 6): 77–93. 30. Chouinard G, Jones B, Remington G. A Canadian multicenter placebo-controlled study of fixed doses of resperidone and amisulpride in treatment of chronic schizophrenic patients. J Clin Psychopharmacol 2003; 13: 25–40. 31. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clini Psychopharmacol 2000; 15 (1): 13–22. 32. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry 2004; 12 (1): 74–6. 33. Croissant B, Hermann D, Olbrich R. Saving potential of clozapine due to combination with amisulpride. Psychopharmakotherapie 2001; 8 (3): 128–30. 34. Danion J, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999; 156: 610–6. 35. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64. 36. Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E. Effects of acute and repeated administration of amisulpride, a dopamine D2 D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J Pharmacol Exp Ther 1998; 287 (1): 51–7. 37. Freeman H. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies. Int Clini Psychopharmacol 1997; 12 (Suppl. 2): 11–7. 38. Geddes J, Freemantle N, Harrison P et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. Br Med J 2000; 321: 1371–6. 39. Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Ther 2007; 24 (1): 1–13. 40. Guo N, Guo W, Guillin O et al. The surface D2-binding profile of the atypical antipsychotic drug amisulpride. J Cereb Blood Flow Metabo 2007; 27 (Suppl. 1): 1003–12. 41. Haro JM, Novick D, Belger M, Ratcliffe M. Antipsychotic type and correlates of antipsychotic treatment discontinuation in the outpatient treatment of schizophrenia. Eur Neuropsychopharmacol 2005; 15 (Suppl. 3): 496. 42. Herrera-Estrella M, Apiquian R, Fresan A et al. The effects of amisulpride on five dimensions of psychopathology patients with schizophrenia: a prospective open-label study. BMC Psychiatry 2005; 5: 22. 43. Hodgson R, Belgamwar R, Al-Tawarah Y, Mackenzie G. Hum Psychopharmacol 2005; 20: 141–7. 44. Huttunen M, Piepponen T, Rantanen H. Risperidone versus amisulpride in treatment of acute schizophrenic episodes: a double-blind parallel – group trial. Acta Psych Scan 2001; 94: 271–7. 45. Isbister GK, Murray L, John S et al. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust 2006; 184 (7): 354–6. 46. Kaempf P, Agelink M, Mass R et al. Amisulpride in addition to clozapine: A retrospective study indicates improved efficacy and good tolerability. Ger J Psychiatry 2003; 6 (3): 64–8. 47. Kaempf P, Agelink M, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005; 38: 39–40. 48. Kontaxakis V, Havaki-Kontaxaki B, Ferentinos P et al. Switching to amisulpride monotherapy for treatment-resistant schizophrenia. Eur Psychiatry 2006; 21 (3): 214–7. 49. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006; 21 (2): 99–103. 50. La Fougere C, Meisenzahl E, Schmitt G et al. D2-receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: A 123 I-iodobenzamide SPECT study. J Nucl Med 2005; 46 (6): 1028–33. 51. Lecrubier Y, Azorin M, Bottai T et al. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia. Neuropsychobiology 2001; 44 (1): 41–6. 52. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amilsulpride versus imipramine and placebo in dysthymia and major depression. J Affect Disord 1997; 43 (2): 95–103. 53. Lecrubier Y, Quintin P, Bouhassira M et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: Olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatrica Scand 2006; 114 (5): 319–27. 54. Lerner V, Bergman J, Borokhov A et al. Augmentation with Amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005; 28: 66–71. 55. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analisys of randomized controlled trials. Int J Neuropsychopharmacol 2004; 7 (Suppl. 1): 15–20. 56. Leucht S, Abraham D. Efficacy and extrapyramidal side-effect of the new antipsychotics olanzapine, quetiapine, resperidone, amisulpride and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Scizophr Res 2002; 35: 51–68. 57. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373 (9657): 31–41. 58. Leucht S, Pitschel-Walz G, Abraham D et al. Efficacy and extrapyramidal side-effects of the new atypical antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68. 59. Leucht S, Pitschel-Walz G, Engel R et al. Amisulpride, an Unusual «Atypical» Antipsychotic: A Meta-Analisys of Randomized Controlled Trials. Am J Psychiatry 2002; 159: 180–90. 60. Loo H, Poirier-Littre M, Theron M et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170: 18–22. 61. Matthiasson P, Costa D, Erlandsson K et al. The relationship between dopamine D2 receptor occupancy and clinical response in amisulpride augmentation of clozapine non-response. J Psychopharm 2000; 14 (Suppl. 3): 57. 62. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18: 933–56. 63. Moller HJ. Эффективность амисульприда при лечении шизофрении. Обзор литературы (расширенный реферат). Психиатрия и психофармакотерапия. 2004; 3. 64. Moller H, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997; 132 (4): 396–401. 65. Montgomery S. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Int Clin Psychopharmacol 2002; 17 (Suppl. 4): 9–19. 66. Mortimer A.M. Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatric Disease and Treatment 2009; 5: 267–77. 67. Mortimer A, Martin S, Loo H et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004; 19: 63–9. 68. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev 2002; 2: D001357. 69. Munro J, Matiasson P, Osborne S et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110: 292–8. 70. Naber D, Arlt J, Lambert M. Амисульпирид как эффективное и безопасное средство, применяемое в качестве препарата выбора при длительном лечении больных шизофренией (расширенный реферат). Психиатрия и психофармакотерапия. 2004; 5. / Amisul'pirid kak effektivnoe i bezopasnoe sredstvo, primeniaemoe v kachestve preparata vybora pri dlitel'nom lechenii bol'nykh shizofreniei (rasshirennyi referat). Psychiatry and psichopharmacotherapy. 2004; 5. [in Russian] 71. Naber D, Lambert M, Roesch F et al. Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease. Eur Neuropsychopharmacol 2004; 14 (Suppl. 3): 256. 72. Nuss Ph, Hummer M, Tessier C. The use of amisulpride in the treatment of acute psychosis. Therapeutics and Clinical Risk Management 2007; 3 (1): 3–11. 73. Olie J-P, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: Results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006; 21 (3): 143–51. 74. Paes De Sousa M. Amisulpride in dysthymia: Results of a naturalistic study in general practice. Eur Psychiatry 1996; 11 (Suppl. 3): 145–7. 75. Paillere-Martinot M. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Pshychiatry 1999; 155: 130–3. 76. Pani L, Gessa G. The role of dopamine in the biological basis of dysthymia. Ital J Psychiatr Behav Sci 1998; 8 (1): 5–9. 77. Pedrosa Gil F, Grohmann R, Rüther E. Asymptomatic bradycardia associated with amisulpride. Pharmacopsychiatry 2001; 34 (6): 259–61. 78. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121–8. 79. Perrault G, Depoortere R, Morel E et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 73–82. 80. Peuskens J, Bech P, Moller H-J et al. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88 (2): 107–17. 81. Peuskens J, Moller H, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002; 12 (4): 305–10. 82. Puech A, Fleurot O. Amisulpride Study Group. Amisulpride, an atypical, in the treatment of acute exacerbations of schizophrenia: a doseranging study versus haloperidol. Acta Psychiatr Scand 1998; 98: 65–72. 83. Ravizza L. Amisulpride in medium-term treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline. J Psychopharmacol 1999; 13 (3): 248–54. 84. Rocca P, Fonzo V, Ravizza L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 2002; 70 (3): 313–7. 85. Rozenzweig P, Canal M, Patat A et al. A review of pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human Psychopharmacology 2002; 17: 1–13. 86. Schoemaker H, Claustre Y, Fage D et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83–97. 87. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study. J Affect Disord 1998; 48 (1): 47–56. 88. Smeraldi E, Haefele E, Crespi G et al. Amisulpride versus fluoxetine in dysthymia: Preliminary results of adouble-blind comparative study. Eur Psychiatry 1996; 11 (Suppl. 3): 141–3. 89. Speller J, Barnes T, Curson D et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997; 171: 564–8. 90. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005; 20 (5): 243–51. 91. Stone J, Bressan R, Erlandsson K et al. Non-uniform blockade of intrastriatal D2 D3 receptors by risperidone and amisulpride. Psy-chopharmacology 2005; 180 (4): 664–9. 92. Storosum J, Elferink A, Van Zwieten B et al. Amisulpride: Is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 2002; 28 (2): 193–201. 93. Taylor DM, McAskill R. Atypical antipsychotics and weight gain a systematic review. Acta Psychiatr Scand 2000; 101: 416–32. 94. Thomas P, Vieta E. Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. Neuropsychiatric Disease Treatment. 2008; 4 (3): 675–86. 95. Tiihonen J, Whalbeck K, Lonnquisvt J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333 (7561): 224. 96. Tran PV, Hamilton SH. Double-blind comparision of olanzapine versus amisulpride in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 2000; 17: 407–18. 97. Tufan AE, Yalug I. Clozapine augmented with amisulpride in 3 cases of treatment-resistant early- and very early-onset schizophrenia. Psychiatr Danub 2013; 25 (1): 76–9. 98. Vaiva G, Thomas P, Llorca P et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res 2002; 115 (1–2): 37–48. 99. Vanelle J-M, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006; 21 (8): 523–30. 100. Ward DI. Two cases of amisulpride overdose: a cause for prolonged QT syndrome. Emerg Med Australas 2005; 17 (3): 274–6. 101. Wetzel H, Grunder G. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double- blind controlled study comparing a selective D2-like antagonist to a mixed D1/D2-like antagonist. Psychopharmacology 1998; 137: 223–32. 102. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006; 16 (4): 281–7. 103. Ziegenbein M, Sieberer M, Kuenzel H et al. Augmentation of Clozapine With Amisulpride in Patients With Treatment-Resistant Schizophrenia: an Open Clinical Study. German J Psychiatry 2006; 9: 17–21. 104. Zink M, Henn F, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19 (1): 56–8. 105. Zink M, Knopf U, Henn F, Thome J. Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia – Case Reports and Review of the Literature. Pharmacopsychiatry 2004; 37 (1): 26–31.